ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IMNM Immunome Inc

14.99
0.28 (1.90%)
01 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Immunome Inc NASDAQ:IMNM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.28 1.90% 14.99 15.03 15.20 15.81 14.61 15.32 1,588,124 01:00:00

Immunome to Present at 2024 Bank of America Healthcare Conference

08/05/2024 1:00pm

Business Wire


Immunome (NASDAQ:IMNM)
Historical Stock Chart


From May 2024 to Jun 2024

Click Here for more Immunome Charts.

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Immunome, Inc.

Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, and radioligand therapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.

For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.

Investor Contact Max Rosett Interim Chief Financial Officer investors@immunome.com

1 Year Immunome Chart

1 Year Immunome Chart

1 Month Immunome Chart

1 Month Immunome Chart